232 related articles for article (PubMed ID: 9698051)
1. Lysergic acid diethylamide (LSD) is a partial agonist of D2 dopaminergic receptors and it potentiates dopamine-mediated prolactin secretion in lactotrophs in vitro.
Giacomelli S; Palmery M; Romanelli L; Cheng CY; Silvestrini B
Life Sci; 1998; 63(3):215-22. PubMed ID: 9698051
[TBL] [Abstract][Full Text] [Related]
2. A sensitive assay for studying dopaminergic activity in cultures of rat pituitary cells.
Giacomelli S; Braghiroli L; Ponzianelli A; Koppenaal DW; De Feo G
J Pharm Pharmacol; 1997 Mar; 49(3):319-21. PubMed ID: 9231354
[TBL] [Abstract][Full Text] [Related]
3. Activation of D2 dopamine receptors inhibits estrogen response element-mediated estrogen receptor transactivation in rat pituitary lactotrophs.
Ishida M; Mitsui T; Izawa M; Arita J
Mol Cell Endocrinol; 2013 Aug; 375(1-2):58-67. PubMed ID: 23701824
[TBL] [Abstract][Full Text] [Related]
4. Lysergic acid diethylamide: evidence for stimulation of pituitary dopamine receptors.
Meltzer HY; Fessler RG; Simonovic M; Doherty J; Fang VS
Psychopharmacology (Berl); 1977 Aug; 54(1):39-44. PubMed ID: 143671
[TBL] [Abstract][Full Text] [Related]
5. Interactions between lysergic acid diethylamide and dopamine-sensitive adenylate cyclase systems in rat brain.
Hungen KV; Roberts S; Hill DF
Brain Res; 1975 Aug; 94(1):57-66. PubMed ID: 238721
[TBL] [Abstract][Full Text] [Related]
6. D2 dopamine-receptor-mediated inhibition of proliferation of rat lactotropes in culture is accompanied by changes in cell shape.
Arita J; Hashi A; Hoshi K; Mazawa S; Suzuki S
Neuroendocrinology; 1998 Sep; 68(3):163-71. PubMed ID: 9734000
[TBL] [Abstract][Full Text] [Related]
7. Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis.
Marona-Lewicka D; Thisted RA; Nichols DE
Psychopharmacology (Berl); 2005 Jul; 180(3):427-35. PubMed ID: 15723230
[TBL] [Abstract][Full Text] [Related]
8. Dopaminergic stimulation of prolactin release.
Denef C; Manet D; Dewals R
Nature; 1980 May; 285(5762):243-6. PubMed ID: 6154895
[TBL] [Abstract][Full Text] [Related]
9. Implication of D2-like dopaminergic receptors in the median eminence during the establishment of long-day inhibition of LH secretion in the ewe.
Bertrand F; Thiery J; Picard S; Malpaux B
J Endocrinol; 1999 Nov; 163(2):243-54. PubMed ID: 10556774
[TBL] [Abstract][Full Text] [Related]
10. Activation of Go-coupled dopamine D2 receptors inhibits ERK1/ERK2 in pituitary cells. A key step in the transcriptional suppression of the prolactin gene.
Liu JC; Baker RE; Sun C; Sundmark VC; Elsholtz HP
J Biol Chem; 2002 Sep; 277(39):35819-25. PubMed ID: 12121979
[TBL] [Abstract][Full Text] [Related]
11. Dopamine decreases striatal enkephalin turnover and proenkephalin messenger RNA abundance via D2 receptor activation in primary striatal cell cultures.
Kowalski C; Giraud P
Neuroscience; 1993 Apr; 53(3):665-72. PubMed ID: 8487949
[TBL] [Abstract][Full Text] [Related]
12. Evidence that melatonin acts in the pituitary gland through a dopamine-independent mechanism to mediate effects of daylength on the secretion of prolactin in the ram.
Lincoln GA; Clarke IJ
J Neuroendocrinol; 1995 Aug; 7(8):637-43. PubMed ID: 8704738
[TBL] [Abstract][Full Text] [Related]
13. Ethanol and estradiol modulate alternative splicing of dopamine D2 receptor messenger RNA and abolish the inhibitory action of bromocriptine on prolactin release from the pituitary gland.
Oomizu S; Boyadjieva N; Sarkar DK
Alcohol Clin Exp Res; 2003 Jun; 27(6):975-80. PubMed ID: 12824819
[TBL] [Abstract][Full Text] [Related]
14. D2 Dopamine receptor subtype mediates the inhibitory effect of dopamine on TRH-induced prolactin release from the bullfrog pituitary.
Nakano M; Minagawa A; Hasunuma I; Okada R; Tonon MC; Vaudry H; Yamamoto K; Kikuyama S; Machida T; Kobayashi T
Gen Comp Endocrinol; 2010 Sep; 168(2):287-92. PubMed ID: 20553721
[TBL] [Abstract][Full Text] [Related]
15. The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT
De Gregorio D; Posa L; Ochoa-Sanchez R; McLaughlin R; Maione S; Comai S; Gobbi G
Pharmacol Res; 2016 Nov; 113(Pt A):81-91. PubMed ID: 27544651
[TBL] [Abstract][Full Text] [Related]
16. Dopaminergic inhibition of catecholamine secretion from chromaffin cells: evidence that inhibition is mediated by D4 and D5 dopamine receptors.
Dahmer MK; Senogles SE
J Neurochem; 1996 Jan; 66(1):222-32. PubMed ID: 8522958
[TBL] [Abstract][Full Text] [Related]
17. Activation of D1 and D2 dopamine receptors increases the activity of the somatostatin receptor-effector system in the rat frontoparietal cortex.
Izquierdo-Claros RM; del Boyano-Adánez M; Arilla-Ferreiro E
J Neurosci Res; 2000 Oct; 62(1):91-8. PubMed ID: 11002291
[TBL] [Abstract][Full Text] [Related]
18. Differential actions of dopamine receptor subtypes on gonadotropin and growth hormone release in vitro in goldfish.
Chang JP; Yu KL; Wong AO; Peter RE
Neuroendocrinology; 1990 Jun; 51(6):664-74. PubMed ID: 2141920
[TBL] [Abstract][Full Text] [Related]
19. Dopaminergic control of angiotensin II-induced vasopressin secretion in vitro.
Rossi NF
Am J Physiol; 1998 Oct; 275(4):E687-93. PubMed ID: 9755089
[TBL] [Abstract][Full Text] [Related]
20. Effects of the dopamine stabilizers (S)-(-)-OSU6162 and ACR16 on prolactin secretion in drug-naive and monoamine-depleted rats.
Rung JP; Rung E; Johansson AM; Svensson K; Carlsson A; Carlsson ML
Naunyn Schmiedebergs Arch Pharmacol; 2011 Jul; 384(1):39-45. PubMed ID: 21533991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
